Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology.
- Author:
Hiroaki KAJIYAMA
1
;
Kiyosumi SHIBATA
;
Mika MIZUNO
;
Tomokazu UMEZU
;
Shiro SUZUKI
;
Ryuichiro SEKIYA
;
Kaoru NIIMI
;
Hiroko MITSUI
;
Eiko YAMAMOTO
;
Michiyasu KAWAI
;
Tetsuro NAGASAKA
;
Fumitaka KIKKAWA
Author Information
- Publication Type:Original Article
- Keywords: Chemotherapy; Histologic type; Overall survival; Postrecurrence survival; Recurrent ovarian cancer
- MeSH: Drug Therapy; Drug Therapy, Combination; Humans; Mucins; Ovarian Neoplasms*; Platinum*; Prognosis; Taxoids
- From:Journal of Gynecologic Oncology 2014;25(1):43-50
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: This study was conducted to examine the effects of front-line chemotherapy on overall survival (OS) and postrecurrence survival (PRS) of patients with recurrent ovarian cancer, when stratifying the histologic type. METHODS: Five hundred and seventy-four patients with recurrent ovarian cancer with sufficient clinical information, including front-line chemotherapy, were analyzed. The pathologic slides were evaluated by central pathologic review. The patients were divided into two groups: group A (n=261), who underwent taxane plus platinum, and group B (n=313), who underwent conventional platinum-based chemotherapy without taxanes. RESULTS: The median age was 54 years (range, 14 to 89 years). Group A had significantly better median OS (45.0 months vs. 30.3 months, p<0.001) and PRS (23.0 months vs. 13.0 months, p<0.001) compared to group B. The OS and PRS were similar between the groups in patients with clear cell or mucinous histology. In contrast, among patients with non-clear cell, non-mucinous histologies, the OS and PRS of group A were significantly better than those of group B (OS, p<0.001; PRS, p<0.001). Multivariable analyses revealed that, among patients with non-clear cell, non-mucinous histologies, chemotherapy including taxane and platinum was an independent predictor of favorable survival outcomes. Conversely, in patients with clear cell or mucinous histology, taxane-including platinum-based combination chemotherapy did not improve the OS and PRS compared to a conventional platinum-based regimen which did not include taxanes. CONCLUSION: Since the emergence of taxane plus platinum, the prognosis of patients with recurrent ovarian cancer has improved. However, we here demonstrate that this improvement is limited to patients with non-clear cell, non-mucinous histologies.
